SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that John P. Longenecker, Ph.D., President and Chief Executive Officer, will present at the Biotechnology Industry Organization (BIO) InvestorForum at 3:20 p.m. Pacific time on Wednesday, October 18, 2006. The conference will be held at the Palace Hotel in San Francisco.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)
Dr. Longenecker will provide an overview of Favrille and the clinical trials of its lead compound, FavId(R), for the treatment of B-cell non-Hodgkin's lymphoma (NHL). The Company anticipates an analysis of the secondary endpoint, response improvement, from its pivotal Phase 3 clinical trial of FavId this quarter. A live webcast of the presentation can be accessed at www.favrille.com. The replay will be available approximately one hour after the presentation and will be archived until November 18, 2006.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comFavrille, Inc.CONTACT: Pete De Spain, Associate Director, Investor Relations & CorporateCommunications of Favrille, Inc., +1-858-526-2426, pdespain@favrille.com
Web site: http://www.favrille.com//
